JP2024516679A - 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル - Google Patents

敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル Download PDF

Info

Publication number
JP2024516679A
JP2024516679A JP2023566808A JP2023566808A JP2024516679A JP 2024516679 A JP2024516679 A JP 2024516679A JP 2023566808 A JP2023566808 A JP 2023566808A JP 2023566808 A JP2023566808 A JP 2023566808A JP 2024516679 A JP2024516679 A JP 2024516679A
Authority
JP
Japan
Prior art keywords
biomarker
subject
amount
assessing
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516679A5 (https=
Inventor
グリューネバルト，フェリックス
イェーガー，ヴィクトル・ヨハン・ラウル
クラマー，マルティン
シュッツ，フィリップ
ホルタイ，マリア フォン
ヴェーバー，シュテフェン
ベクマイヤー，ハイケ
ビーンヒューズ－テレン，ウルスラ－ヘンリケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024516679A publication Critical patent/JP2024516679A/ja
Publication of JP2024516679A5 publication Critical patent/JP2024516679A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023566808A 2021-04-30 2022-04-29 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル Pending JP2024516679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171492 2021-04-30
EP21171492.8 2021-04-30
PCT/EP2022/061553 WO2022229422A2 (en) 2021-04-30 2022-04-29 Igfbp7 marker panels for early detection of sepsis

Publications (2)

Publication Number Publication Date
JP2024516679A true JP2024516679A (ja) 2024-04-16
JP2024516679A5 JP2024516679A5 (https=) 2025-04-24

Family

ID=75746434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566808A Pending JP2024516679A (ja) 2021-04-30 2022-04-29 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル

Country Status (5)

Country Link
US (1) US20240219404A1 (https=)
EP (1) EP4330681A2 (https=)
JP (1) JP2024516679A (https=)
CN (1) CN117242349A (https=)
WO (1) WO2022229422A2 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
JP2013515243A (ja) * 2009-12-20 2013-05-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2018532114A (ja) * 2015-10-08 2018-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
JP2020519904A (ja) * 2017-05-07 2020-07-02 アスチュート メディカル，インコーポレイテッド 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
US20090197794A1 (en) 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5722587B2 (ja) 2009-10-13 2015-05-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性脳卒中または一過性脳虚血発作を有する患者における細菌感染の診断のためのプロカルシトニン及び抗生物質治療のガイダンス
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515243A (ja) * 2009-12-20 2013-05-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
JP2018532114A (ja) * 2015-10-08 2018-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
JP2020519904A (ja) * 2017-05-07 2020-07-02 アスチュート メディカル，インコーポレイテッド 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAILEI GUO ET AL.: "MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced i", EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol. 24(1), JPN7026001000, 2019, pages 37, ISSN: 0005811730 *
JAYSHIL J. PATEL ET AL.: "The Association of Serum Bilirubin Levels on the Outcomes of Severe Sepsis", JOURNAL OF INTENSIVE CARE MEDICINE, vol. 30(1), JPN7026001001, 2015, pages 23 - 29, ISSN: 0005811731 *
M. MARTIN-FERNANDEZ ET AL.: "Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock", BJS OPEN, vol. 4(3), JPN7026001002, 2020, pages 524 - 534, ISSN: 0005811732 *
MIAN ZENG ET AL.: "Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis,", THE AMERICAN JOURNAL OF EMERGENCY MEDICINE, vol. 34(3), JPN6026009284, 2016, pages 375 - 380, ISSN: 0005811734 *
RONI LEHMANN-WERMAN ET AL.: "Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA", JCI INSIGHT, vol. 3(12), JPN7026001003, 2018, pages 120687, ISSN: 0005811733 *

Also Published As

Publication number Publication date
WO2022229422A3 (en) 2022-12-15
CN117242349A (zh) 2023-12-15
US20240219404A1 (en) 2024-07-04
WO2022229422A2 (en) 2022-11-03
EP4330681A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
JP2024516678A (ja) 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
JP2024516677A (ja) 敗血症の早期検出用のｎｇａｌマーカーパネル
JP2024516679A (ja) 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル
JP2024515086A (ja) 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
JP2024516001A (ja) 敗血症の早期検出のためのｅｓｍ１マーカーパネル
JP2024516681A (ja) 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
US20240230672A1 (en) Presepsin marker panels for early detection of sepsis
JP2024537774A (ja) 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
WO2023156655A1 (en) Dll1 marker panels for early detection of sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260309